Gold vs US Dollar

Register to chat with like-minded investors on our interactive forums.

Get Started

Byotrol Investors - BYOT

Share Name	Share Symbol	Market	Stock Type
Byotrol Plc	BYOT	London	Ordinary Share

	Price Change	Price Change %	Share Price	Last Trade
	0.00	0.00%	0.125	01:00:00

Open Price	Low Price	High Price	Close Price	Previous Close
0.125	0.125	0.125		0.125

more quote information »

Industry Sector
CHEMICALS

Top Investor Posts

Top Posts
Posted at 10/4/2024 08:41 by bagsandbags @loaf IMV there will be a lot more. AIM just doesn't work any more for small companies and I don't see it changing any time soon. What a mess And it particularly doesn't work for IP/R&D companies because most investors no longer look properly at (or understand) IP/asset-based valuation. All they do is value the company by share price. You only have to read this board to see that. Read Full Thread Reply
Posted at 08/4/2024 18:59 by mudbath The Newlands must be unhappy investors being holders of STT's Totally in addition to their 99.9 % wipe at Byotrol. Read Full Thread Reply
Posted at 08/4/2024 13:55 by football Shell threatens to quit London for New York Oil and gas giant looks at ‘all options’ amid concerns it is under-appreciated by investors Read Full Thread Reply
Posted at 07/4/2024 16:36 by loafofbread Less than 2 years ago they thought 3.25p was a decent price. 35 times more than our current share price Todays price is as artificial as you could get. The second relates to the Convertible Bond. The Group issued a Convertible Bond for GBP1m in July 2022 to new and existing investors in the Company, including Board directors. The Loan Notes have a term of five years, are senior in ranking, unsecured and convertible at investors' option into ordinary shares in the capital of the Company ("Ordinary Shares") at a price of 3.25 pence per Ordinary Share, representing a 30% premium to the mid-price of the Company's share price at close of business on 26 July 2022. The Loan Notes carry a coupon of 9% per annum, payable quarterly in arrears. Based on the issue size of GBP1,000,000, the Loan Notes would, if converted, represent approximately 30,769,230 Ordinary Shares, amounting to 6.8% of the current issued share capital of the Company. However, as the average Byotrol share price since the issue of the Convertible Bond has been below the 3.25p conversion price, these are currently classed as non-dilutive and do not feature in the Denominator calculation above. Read Full Thread Reply
Posted at 03/4/2024 09:14 by clocktower The reason for so many leaving the market I suspect, is that directors have been allowed to get away with fleecing investors through their lifestyle and mining value away from small investors, and even when it can be seen that there is no regulations or accountability for their actions, the market turns a blind eye and allows investors to be defrauded and because the SFO doesn’t look at anything below around £50 million, so it’s become the casino of choice. I do not think that applies in this case, it is just failure to sell in volume and poor margins for the company and resellers. I said sometime ago, it needs new leadership and stakeholders now need to delist and remove the BOD and take control. Read Full Thread Reply
Posted at 28/3/2024 07:36 by 1gw Disappointing, if not completely unexpected. A sad end (proposed) to life as a public company, at least for now. -------------------------------------------- 1gw - 08 Dec 2023 - 09:50:49 - 12378 of 12482 No director purchases (so far), no Investor Meet Company presentation, acknowledgement of "potentially a modest fundraise" and a suggestion also that they are keeping the decision to remain listed under frequent review. Hardly an encouraging background for retail investors to buy, is it? Read Full Thread Reply
Posted at 01/11/2023 09:04 by loafofbread Peel Hunt. Doom Loop. Says it all really! Britain’s small and medium-sized companies are trapped in a “doom loop” that risks destroying a crucial part of the UK’s financial ecosystem, analysts have warned. The pace of decline for listed companies outside the FTSE 100 and FTSE 250 is “relentless221;, according to a report published by Peel Hunt. The investment bank highlighted a 10pc decline in the number of companies on the FTSE’s SmallCap index. This number has declined by 30pc over the last five years. It said markets are being hit by a swirl of negative factors including low valuations, falling liquidity, investors withdrawing their funds and a lack of initial public offerings (IPOs). Charles Hall, head of research at Peel Hunt, said: “The pace of decline is relentless and is likely to continue unless effective action is taken quickly. “We are currently in a doom loop, where valuations are low, liquidity is reducing, investors are seeing withdrawals and there is little desire to IPO.” He called on the Government to bring in reforms to make it more attractive for smaller companies to list in the UK and more lucrative for investors to hold shares in those companies. He added: “It is still significantly more onerous to be listed in terms of costs, bureaucracy, regulations and distraction for management, in stark contrast to private markets, where leverage is typically materially higher, pricing is opaque and there are tax advantages.” Read Full Thread Reply
Posted at 27/10/2023 11:10 by 1gw I hope not. It looks to me like they've been caught out mainly by the delay in Solvay IP revenue coming through, allied to (apparently) a downturn in the market for doing further IP deals. They invested in the business (new staff, virology lab, IP development on seaweed & naturals) on the back of the windfall of pandemic cashflow, fully expecting (afaics) that material Solvay revenue was about to arrive and so they could afford to spend some money getting the product sales business in better shape in anticipation of that. Clearly material Solvay revenue hasn't (yet) arrived and in addition they appear to have been unable to close any new IP deals for the last 15 months, which would have been their other expected source of cash. So that's left them (seemingly) worryingly close to the edge on cashflow. Then the sudden loss of the CEO provides a further hit to sentiment. All this in a market where lots of AIM stocks are beaten up, investors are licking their wounds and there are more apparent investment opportunities (for investors) than there is cash to put into them. And they don't seem to go out of their way (to put it mildly) to attract new investors in. But sentiment could turn round quickly if they can pull off a decent new IP deal and/or announce a material cash receipt from an existing one which allays fears on the cash position and provides some confidence that the current guidance is achievable. Read Full Thread Reply
Posted at 23/8/2023 07:03 by football Todays RNs Wednesday Byotrol PLC Investor Presentation via Investor Meet Company 23/08/2023 7:00am RNS Non-Regulatory TIDMBYOT Byotrol PLC 23 August 2023 RNS Reach Byotrol plc ("Byotrol" or the "Company") Investor Presentation via Investor Meet Company Byotrol plc (AIM: BYOT), the specialist infection prevention and control company is pleased to announce that Vivan Pinto, CEO, David Traynor, Executive Director, and Chris Sedwell, CFO, will provide a live presentation relating to the Full Year Results via Investor Meet Company on 8th Sep 2023 at 11:00am BST. The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation. Investors can sign up to Investor Meet Company for free and add to meet BYOTROL PLC via: Investors who already follow BYOTROL PLC on the Investor Meet Company platform will automatically be invited. For further information, visit www.byotrolplc.com , follow on twitter @byotrol, or contact Read Full Thread Reply
Posted at 26/7/2023 12:07 by 1gw Secondly, byotrol’s approach to investors. I don’t think byotrol deliberately keeps investors in the dark. If you look at the IMC sessions there is a lot of data provided in the presentation packs and they appear to try to answer all investor questions. However, they do not appear to believe that they need to court retail investors by offering more than the regulation 2 sessions per year (full year results around September and interims around December, plus the AGM for those that can make it) or by putting out non-regulatory releases to update investors on implementation of plans. I think in the past this was a cost-benefit decision informed by a view that they wouldn’t need to go to the market for funds in the foreseeable future (remember “sustainably cashflow positive” from their broker). They were (apparently) caught out last year by the post-covid dip in product sales and the delay vs expectations in Actizone (and other IP) revenues and had to seek some funds to maintain growth spend, hence the convertibles issue. They are hamstrung by NDA’s. Having talked to Solvay and seen the same sort of reticence there, I think that is genuine. However, they have repeatedly missed guidance on IP deal delivery, most notably with the profit warnings in FY22. Despite this they continue to be opaque about their forecasts. They have forecast returning to profit this year but there is very little context about the extent to which this (again) assumes delivery of new IP deals. They have put out expectations for FY23, FY24 and FY25 via finnCap, but appear to have missed product sales expectations for the first 6-month period (2H FY23) and have given no quantified sense of how their first big product launch (Anigene) has gone or why we have seen nothing of the expected move into Europe with it. That does little to build investor confidence and it’s perhaps not surprising that, other than little bounces around specific news items (EPA registration, seaweed patent) there has been no sustained recovery in the shareprice. We are coming into the news period of the year, with full year results, AGM and interims. We have a new chairman (TF) and a relatively new CEO (VP). If retail investors want the company to change its approach, then this is the time of year they get a chance to make their views known. I would urge those that feel strongly about it to lobby chairman, CEO and CFO when they get the chance. Read Full Thread Reply

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions